
Dr Ecker on the Investigation of the Microbiome in Pancreatic Cancer
Brett L. Ecker, MD, discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.
Brett L. Ecker, MD, surgical oncologist, member of RWJBarnabas Health Medical Group, Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.
At the
Recent evidence has challenged the traditional notion of the pancreas is a sterile organ, revealing that, particularly in cancer contexts, microbes are often present, typically identified within tumoral cells, he expands. The association of these microbes with altered gene expression linked to metastatic spread and tumor growth prompts the question: are these microbes present in precursor lesions for pancreas cancer? Further questions focus on determining their presence, quantifying them across the dysplastic continuum, identifying species, and assessing microbial diversity, Ecker emphasizes. Moreover, further research should identify how these microbes affect cellular processes. This area of microbial research is relatively nascent, with advancements in technology over the past few years facilitating exploration, he notes.
In collaboration with the Karolinska Institute, Ecker has identified certain onco-bacteria, typically part of the oral microbiota, associated with high-grade dysplasia compared with low-grade dysplasia. To date, Ecker and his group are among the few to publish on this aspect, and anticipate contributing further to the burgeoning field of microbial research in the context of pancreas cancer.


































